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close to the Willingness to Pay threshold, Markov models should be analyzed with 
shorter cycle length or a DES approach adopted to ensure conclusions are robust.
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Model-Based econoMic evaluations in alzheiMeR’s disease : a Review 
of Modeling Methods
Marty R., Roze S.
HEVA HEOR, Lyon, France
Objectives: To review the modeling-based economic evaluations (MB2E) of 
acetylcholinesterase inhibitors (ACE) and memantine (MEM) used in the field of 
Alzheimer’s disease (AD). MethOds: A systematic literature search was carried 
out based on several electronic databases such as Medline or the Cochrane Library 
up to November 2012. Modeling frameworks used to depict the natural history of 
AD and incorporation of treatment effects were qualitatively described and com-
pared. Results: More than thirty MB2E were identified with several local adapta-
tions based on ten original modeling frameworks. First published MB2E were either 
Markov state-transitions models or partition failure time survival models while 
most recent MB2E relied on discrete events simulations. The hallmark of the disease, 
the cognitive dimension, was first introduced to model the disease progression 
mainly based on the Mini Mental State Examination (MMSE) scale. The two other 
fundamental-functional and behavioral-dimensions were taken into account as 
a second step. Models relied on distinct clinical milestones and risk equations to 
extrapolate intermediate clinical endpoints from clinical trials (mainly on cognition 
and function) into long-term final endpoints. These latter were delay in severity, 
loss of patient autonomy, institutionalization, burden of care and quality-adjusted 
life years. Differences occurred as well on the way inter-patient heterogeneity was 
incorporated with a trend towards more micro-simulations technics. Eventually, 
predictors and inter-relations between the several dimensions of the natural history 
of the disease seemed not to be fully captured in the model structures with chal-
lenging needs to assess the resulting potential biases. cOnclusiOns: Advanced 
modeling methods in the field of AD were being introduced to better capture the 
continuous, progressive and multivariate natural history of AD. Further work is war-
ranted given the emerging early diagnosis technics, neuropathological biomarkers 
and targeting therapies.
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Objectives: Previous cost-effectiveness analyses of targeted therapies in meta-
static renal cell carcinoma (mRCC) have been based on randomised trials and 
evaluate just one single treatment-line. The aim of this study was to estimate 
the real-world cost-effectiveness of sequential first- and second-line treatments 
for patients with mRCC using a patient-level simulation (PLS) model. MethOds: 
Based on patient-level data from a Dutch population-based registry, a PLS model 
was developed that comprised entities (i.e. patients with mRCC), attributes 
assigned to the entities (i.e. prognostic factors), and events (i.e. second-line treat-
ment or death). Patients were repeatedly simulated from the model and time-to-
event was estimated using a lognormal distribution. A separate sampling process 
was used to determine which type of event occurred. Time to death following 
second-line treatment was modelled using a Weibull distribution. Lifetime health 
care costs were modelled using patient-level data from the registry. Results: In 
current daily practice, 50% (341/686) of patients did not receive any targeted ther-
apy and 42% (291/686) received sunitinib as first-line therapy. In the second line, 
31% (33/107) were treated with sorafenib and 31% (33/107) with everolimus. Mean 
overall survival (OS) was 13.6 months and mean costs were € 69,622 for all patients. 
In a strategy where all patients are treated according to clinical guidelines, mean 
OS was 15.2 months and costs were € 91,059. This meant an increase in OS (1.6 
months) and costs (€ 21,437) compared to current practice, with an incremental 
cost-effectiveness ratio of € 159,107 per life-year gained. Probabilistic sensitiv-
ity analyses showed the robustness of these results. cOnclusiOns: A complete 
disease model and real-world data are essential in estimating real-world cost-
effectiveness. Our PLS model allows comparisons between treatment strategies 
spanning multiple treatment lines, which will ultimately help to reveal the optimal 
strategy. For example, guidelines-based treatment appears to increase both OS and 
costs compared to current daily practice.
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Objectives: Long-term cardiovascular outcomes studies are routinely under-
taken to demonstrate safety in all new diabetes therapies. Given that diabetes 
models are extensively validated to contemporary outcomes trials they offer the 
potential to inform on design of new trials. The objective of this study was to 
use an established diabetes model to explore the relationship between levels 
of glycaemic control, major adverse cardiovascular events (MACE) and sample 
size. MethOds: The IMS CORE Diabetes Model (CDM) a validated and widely used 
simulation model was initiated with patient level data (PLD) drawn from NHANES. 
The model was run with a five-year time horizon and the sample sizes required 
to detect a difference in MACE (defined as myocardial infarction, stroke or CV 
death) at the 5% level as a function of change in HbA1c evaluated. Results: PLD 
from NHANES was available on 1853 subjects with mean (SD) age 63.6(12.1) years, 
53% male, duration of diabetes 9.6(8.5) years, baseline HbA1c 7.4% (1.8), systolic 
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Objectives: To evaluate cost-effectiveness of pneumococcal vaccination of 
children with 10-valent (PHiD-CV) compared with 13-valent pneumococcal con-
jugate vaccine (PCV-13). MethOds: A Markov cohort model which simulates in 
a Bulgarian birth cohort the disease process of invasive disease (ID) (meningitis 
and bacteremia), community acquired pneumonia (CAP), and acute otitis media 
(AOM) over life-time caused by S. pneumoniae and non-typeable Haemophilus 
Influenzae (NTHi). The cohort model essentially considers the perspective of the 
health care payer. Bulgarian specific epidemiological and demographic data and 
data from other country sources were obtained for the model. Base case assump-
tions include estimates of pneumococcal and NTHi infection rates as well as vaccine 
efficacy based on published literature, 94% vaccine coverage, herd protection and a 
(3+1) vaccination schedule. One-way sensitivity analyses performed to assess the 
impact of changes in key model assumptions. Results: PHiD-CV and PCV-13 are 
projected to prevent 29.4 and 29.9 cases of invasive diseases respectively and 437 
and 434 bacteremia hospitalizations respectively . PHiD-CV in comparison with 
PCV-13 is projected to prevent additional 9393 cases of AOM, 426 myringotomies 
and 2801 GP visits. Vaccinating a birth cohort with PHiD-CV is expected to gener-
ate 41 more QALYs compared to PCV-13. The estimated total savings for health 
care system are 1.77 mil Euro. The PHiD-CV is dominant in comparison with PCV-
13. Sensitivity analyses indicate that GP visits for AOM and efficacy vs. AOM due 
to Streptococcus Pneumonia non-Vaccine Types Sp nVT have biggest impact on 
results. cOnclusiOns: Overall, PHiD-CV is expected to have betterI impact and 
under the given assumptions, PHiD-CV dominates PCV-13 because it also has a 
larger cost offsets.
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Objectives: Analysing patient level data (PLD) within cost-effectiveness (CE) mod-
els offers the potential to better understand patient profiles associated with greatest 
health economic benefit. The objective of this study was to contrast the application 
of average treatment efficacy profiles compared to patient level treatment efficacy in 
assessing the CE of insulin glargine (IG) versus Neutral protamine Hagedorn (NPH) in 
Type 2 diabetes mellitus (T2DM) MethOds: This study used the IMS Core Diabetes 
Model (CDM), a validated and established diabetes model to evaluate the CE of 
switching to IG from NPH using published effectiveness data from a large population 
based cohort. Average HbA1c reduction after switching from NPH was -0.18% and 
weight gain was 0.5kg. Annual diabetes specific therapy cost was £573 (IG) versus 
£320 (NPH). A PLD extract was obtained from NHANES and the CE of IG versus NPH 
assessed applying (a) overall mean treatment effects (MTE) and (b) baseline HbA1c, 
BMI and sex adjusted treatment effects (ATE). Costs (2012 UK£) and benefits were 
discounted at 3.5%. Results: For the MTE and ATE scenarios, the incremental cost 
effectiveness ratio (ICER) was £28,925 and £57,279 respectively. For MTE scenario, 
765 (41.1%) of subjects were CE at the £20,000 willingness to pay (WTP) and 47 IG 
subjects (6.1%) were both cost saving with increased health benefit. Using ATE, 
525 (28.2%) were CE at the £20,000 WTP threshold with 164 (31.2%) of IG subjects 
identified as both cost saving with increased health benefit. The odds ratio (OR) of 
being both cost saving with greater health benefit was significantly associated with 
age, OR= 0.89(0.87-0.93) and baseline HbA1c, OR= 6.11 (4.64-8.03). cOnclusiOns: 
The identification of patient characteristics associated with greater potential for 
health gain and reduced cost is an important goal. The analysis of PLD alongside 
simulation model output provides an additional mechanism for informing health 
care decision-making.
PRM70
coMPaRison of MaRkov and discRete event siMulation Modeling 
techniques with aPPlication to cost effectiveness analyses
Chrosny W.(1, Stevenson M.2, Munzer A.1
1TreeAge Software, Inc, Williamstown, MA, USA, 2University of Sheffield, Sheffield, UK
Objectives: To assess the bias introduced to absolute costs, absolute QALYs and 
the incremental cost effectiveness ratio (ICER) associated with Markov models, 
compared with discrete event simulation (DES) models. To investigate how such 
biases are a function of cycle length and half-cycle correction. MethOds: A hypo-
thetical three health state model was constructed using both Markovian and DES 
approaches. Costs and utility were assigned to each health state and the ICERs 
between two treatment strategies were estimated. Six Markov models using dif-
ferent cycle lengths (1 month, 3 month, 1 year), and with and without half cycle 
correction were constructed. Differences in the absolute costs and QALYs generated 
between each Markov model were compared with the DES approach and the ICERs 
generated by each model were compared. Results: Markov model simulation was 
shown to introduce biases in the absolute costs and QALYs when compared with a 
DES approach. The bias was related to the duration of the time cycle with the results 
converging to the DES values as the time cycle was reduced. The initial bias in cost 
fell from 14% to less than 1%; QALY bias was consistently below 1%. The ICERs show 
bias between 2.4% and 9.6% when using a 1 year cycle and between 0.6% - 5.4% when 
using a 1 month cycle. The half-cycle correction reduced absolute bias between 2% 
- 10%, the ICERs were not affected. The time cycle duration was the primary param-
eter in reducing bias. cOnclusiOns: Markov models introduce bias due to the 
simplifying assumptions of fixed cycle length and half cycle correction; DES models 
do not suffer the same biases. It is suggested that when the ICERs produced are 
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structural equation models (ESEM), a method that can be considered a strong 
alternative to the exclusive use of exploratory factor analysis (EFA) and confirma-
tory factor analysis (CFA) in patient related outcomes measurement. By combining 
the steps of EFA and CFA in one unified approach, ESEM saves significant time 
and effort usually invested in separate iterations of EFA and CFA. MethOds: 
One hundred replications of ESEM models were carried out for variations of sam-
ple size and latent factors. Simulation study 1 examined the behavior of ESEM 
parameter estimates by changing the values of rotation constant (0.01, 0.001 and 
0.0001) in Geomin rotation for a three-factor single group model and for N= 300 and 
1000. Simulation study 2 evaluated the behavior of ESEM parameter estimates for 
multi-group models using three- and four-factor models for N= 150 and 500 per 
group. Bias, Mean Square Errors (MSE) and standard errors were used to evaluate 
accuracy of parameter recovery. Item parameters were generated from 27 items 
belonging to a pilot graduate creativity instrument. Results: For study 1, Geomin 
rotated parameter estimates of factor loadings, means and covariances produce 
higher MSEs than the follow up Target rotations. In study 2, the parameter esti-
mates for ESEM Geomin show small sample size bias for some parameters while 
the standard errors produced correct coverage for all parameters under Target 
rotation method for large N= 500 per group. cOnclusiOns: Overall, there was 
accurate recovery of parameter estimates in the smallest sample of 300 especially 
in the multi-group models specifically when Geomin rotations were employed. 
This bodes well for analysis of real data and for the study of measurement invari-
ance across groups. Future studies could include the examination of number of 
items affecting recovery of parameter estimates.
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Objectives: Historically, cardiovascular (CV) endpoints, including myocardial 
infarction and stroke, have often been included indirectly in cost-effectiveness 
analyses (CEA) based on surrogate endpoints from clinical trials, such as cho-
lesterol levels, blood pressure or glycemic control. With the availability of out-
comes trials sufficiently powered to show differences in CV endpoints, there 
is an increasing need to incorporate these data directly into CEA. This study 
investigated approaches available in the published literature for modeling CV 
endpoints directly based on outcomes data. MethOds: A systematic review of 
cost-effectiveness models for cardiovascular interventions published in the past 
5 years was conducted in PubMed and Embase using a predefined search strategy. 
Only studies in English language directly integrating trial data on CV endpoints 
from randomized clinical trials were considered. For each study that met the 
inclusion criteria, clinical input characteristics and the modeling approach were 
summarized and evaluated. Results: Twenty-three papers were identified for 
final review, including studies of antithrombotic, heart failure, and lipid lowering 
therapies. Methodologically, decision trees, Markov models (cohort and individual 
patient), discrete event simulations as well as hybrids of these approaches were 
used. Event rates were incorporated either as constant rates, time-dependent 
risks, or risk equations based on patient characteristics. Although potentially more 
accurately reflecting the trial data, risks dependent on time and/or patient charac-
teristics were only used where feasible (major event rates > 1%/year) and practical 
(models with fewer than seven health states). Models incorporating data from 
infrequent events or with numerous health states generally preferred constant 
event rates. cOnclusiOns: When the risk of CV events is low and/or the disease 
state is explicitly modeled in detail, constant events rates were most common. 
For heterogeneous populations or when CV event risk is high, simpler model 
structures were generally accompanied by patient- or time-dependent event rates 
where permitted by the available data.
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Objectives: Correlated parameters are a common feature in economic 
models, but no standard sensitivity analysis (SA) exists to show their impact on 
cost-effectiveness. The one-way SA only varies one parameter at a time and ignores 
correlation while the probabilistic SA is typically used to address overall uncertainty. 
The objective of this study is to propose a standard method for visualising the 
impact of one variable consisting of two correlated parameters in cost-effectiveness 
analysis. MethOds: A model evaluating the cost-effectiveness of a cancer product 
was used. Using the Cholesky decomposition, 1,000 correlated random draws were 
generated from the distributions of the intercept and slope of a linear function 
determining survival in the model. Each pair was inputted in the model to yield the 
percentage of simulations below accepted thresholds. Results were visualised using 
R in a scatter plot with both parameters on a separate axis. Shaded areas repre-
sented the percentage of simulations below accepted cost-effectiveness thresholds 
and an ellipse was added representing 80% of the simulated parameter combina-
tions. A conventional one-way SA was performed for comparison. Results: The 
one way SA found wide ranges of incremental cost-effectiveness ratios (ICER) for 
the intercept and slope parameters (£10,000 - £50,000 per QALY gained). The method 
described above found that 78% of the simulated pairs resulted in ICERs below 
£20,000 per QALY gained, and 93% in ICERs below £30,000. The scatter plot visualised 
the combined uncertainty and their impact on the ICER. A limitation is that the 
visualisation only allows for 2 correlated parameters. Also, the use of R to generate 
the graph complicates incorporation of this SA in Excel models. cOnclusiOns: 
A method was demonstrated to show the impact of correlated parameters in cost-
effectiveness analyses. This method may be especially helpful when assessing the 
uncertainty around parametric survival fits.
blood pressure 134.9mmHg (22.0) and total cholesterol of 189.8 mg/dl (48.7). The 
expected five-year cumulative MACE event rate was 9.2% and HbA1c reductions 
of 0.5%, 1.0% and 1.5% produced relative risk reductions of 7.5%, 9.0% and 10.6% 
respectively. At the 5% level, the number of patients required to detect a signifi-
cant reduction in MACE events was 17,786, 11,758 and 1,912 for HbA1c reductions 
of 0.5%, 1.0% and 1.5% respectively. On average, each half-unit change in HbA1c 
required an additional 7,937 subjects to detect a significant difference in MACE 
event rate. cOnclusiOns: Given the requirement to extensively validate health 
economic models to contemporary outcomes studies it is an obvious extension 
to use these models to inform on the design of clinical trials. These models offer 
considerable flexibility in the evaluation of sample size requirements in terms of 
expected changes in modifiable risk factors.
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Objectives: Clinical studies indicate switching to a second biologic or combination 
therapy with an immunosuppressant after failure of first biologic can be effective 
in patients with moderate to severe plaque psoriasis not responding to the first bio-
logic. MethOds: A systematic literature review was performed to assess treatment 
pathways included in cost-effectiveness (CE) estimates of biologic treatments of mod-
erate to severe psoriasis and compare these pathways with those recommended 
in psoriasis treatment guidelines. Results: Twenty-one CE modeling studies were 
identified. Of these 10 estimated incremental cost per responder for > = 1 biologics 
over time horizons varying from 12 weeks to 18 months. Treatment pathways were 
considered not relevant in these studies. In 11 studies with time horizons up to 10 
years where treatment pathways were considered, 5 studies included a switch to non-
systemic therapy or best supportive care after failure of the initial biologic. In 6 of 11 
studies, failure of the initial biologic was followed by monotherapy with a second-line 
biologic - one of the recommendations in current treatment guidelines. In only 1 of 
6 studies that considered treatment sequencing was the efficacy of the second-line 
biologic adjusted downwards compared to first line treatment. None of the cost-
effectiveness analyses included dose titration with the first-line biologic or combina-
tion therapy with a biologic plus methotrexate or phototherapy after failure of the 
first-line biologic as recommended in some treatment guidelines. cOnclusiOns: 
In most long term CE studies, failure of the first biologic was followed by biologic 
monotherapy of the second, without efficacy adjustment. Some treatment guidelines 
support dose titration or combination treatment after failure of a first-line biologic. 
Nevertheless, these options were not included in the published CE models with time 
horizons up to 10 years. For decision makers there may be a need for more extensive 
models where such strategies are allowed.
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of dRug-eluting stents veRsus BaRe-Metal stents: a systeMatic 
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Objectives: Drug-eluting stents (DES) and bare-metal stents (BMS) are both used 
widely in percutaneous coronary interventions. However, cost-effectiveness analy-
ses of DES versus BMS conflict about whether the reduction in repeat revascu-
larizations of DES versus BMS offsets the initial higher treatment costs of DES. A 
systematic review was performed to examine whether modelling methods influ-
enced the cost-effectiveness of DES versus BMS. MethOds: We reviewed modelling 
studies published until January 2012 that compared the costs and consequences 
of DES versus BMS. General information (e.g. funding) and modelling methods 
used, related to the framing of the economic evaluation (e.g. population and inter-
vention characteristics, time horizon) and parameterisation of the models were 
extracted from the relevant studies for each of the individual analyses performed 
in the studies. Associations between these characteristics and the incremental 
costs and effectiveness were explored using regression analysis. We also exam-
ined whether the results were associated with the quality of the models based on 
the Philips et al. (2006) checklist. Results: Fifteen eligible studies accounted for 
498 separate analyses, in which the incremental cost-effectiveness ratios ranged 
from DES being dominated by BMS to DES being dominant. The most important 
predictors significantly associated with these differences were several population 
and procedure characteristics, funding and assumptions concerning stent efficacy. 
The results and conclusions of individual studies corresponded with the findings 
of this meta-level systematic review. Overall quality of the models was moderate 
(55%±17%) and significantly negatively associated with repeat revascularizations 
avoided. cOnclusiOns: Models are important to obtain valid estimates of the 
cost-effectiveness of DES versus BMS, and framing decisions (e.g. time horizon) 
and quality of the models both influence incremental costs and effects. The most 
influential parameters are identified with this systematic review and we showed 
the need of examining those parameters and of performing a quality check when 
interpreting the results.
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exPloRing geoMin and taRget Rotation techniques on vaRiations of 
eseM Models
Sen R.
Adelphi Values, Boston, MA, USA
Objectives: This simulation study evaluates the impact of Geomin and Target 
rotation criteria on factor loading matrices in the recently developed exploratory 
